Quantcast

Latest Trubion Stories

2009-05-18 15:28:00

SEATTLE, May 18 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN) announced today that data from the re-treatment portion of a Phase 2b study (15002) of TRU-015 for rheumatoid arthritis will be presented on June 11 at the 2009 European League Against Rheumatism (EULAR) annual meeting in Copenhagen, Denmark. A copy of the abstract is now available at http://www.eular.org/. (Logo: http://www.newscom.com/cgi-bin/prnh/20090320/TRUBIONLOGO) Data from the first course of...

2009-05-14 17:00:00

Phase 1: Encouraging Results Observed in CLL Patients Treated With Low Doses of TRU-016 Preclinical Efficacy: TRU-016 is Additive or Synergistic in Combination with Established Therapeutics Preclinical Mechanism Apoptosis in CLL Cells Occurs Via Distinct Mechanism Compared With Other Therapeutics SEATTLE, May 14 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN) announced today the acceptance of three data presentations on its proprietary product candidate, TRU-016,...

2009-05-07 15:00:00

SEATTLE, May 7 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN) today announced financial results for its first quarter ended March 31, 2009. (Logo: http://www.newscom.com/cgi-bin/prnh/20090320/TRUBIONLOGO) First-Quarter 2009 Financial Results Revenue for the first quarter of 2009 was $4.2 million compared with $4.0 million for the first quarter of 2008. Revenue in the first quarter of 2009 was earned through the company's strategic collaboration with Wyeth...

2009-04-30 15:00:00

SEATTLE, April 30 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN) today announced that it plans to issue earnings results for the first quarter ended March 31, 2009, after the close of market on May 7, 2009. The company's earnings conference call will take place May 7, 2009, at 2 p.m. PDT (5 p.m. EDT). (Logo: http://www.newscom.com/cgi-bin/prnh/20090320/TRUBIONLOGO) Both live events will be available for viewing on Trubion's website at http://investors.trubion.com....

2009-04-22 15:24:00

SEATTLE, April 22 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN) announced today presentation of preclinical data regarding its SCORPION(TM) multispecific therapeutic technology at the 100th Annual Meeting of the American Association of Cancer Research (AACR) in Denver. The data presented demonstrated the selectivity and high potency of the bispecific CD79BxDR SCORPION molecule, its differentiation from monospecific approaches, and its potential as a therapeutic for...

2009-04-16 15:00:00

SEATTLE, April 16 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN) announced today that it will present data regarding its SCORPION(TM) multispecific therapeutic technology at the 100th Annual Meeting of the American Association of Cancer Research (AACR) in Denver, April 18-22, 2009. (Logo: http://www.newscom.com/cgi-bin/prnh/20090320/TRUBIONLOGO) The company will present data demonstrating the selectivity and high potency of the bispecific CD79BxDR SCORPION molecule...

2009-03-25 15:00:00

SEATTLE, March 25 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN) announced today that its collaboration partner Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), has initiated a Phase 1 clinical trial of SBI-087, Trubion's next generation CD20 drug candidate, for the treatment of systemic lupus erythematosus (SLE). Based on Trubion's Small Modular ImmunoPharmaceutical (SMIP(TM)) technology, SBI-087 is also being evaluated in a Phase 1 clinical trial for...

2009-03-12 15:00:00

SEATTLE, March 12 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN) today announced financial results for its fourth quarter and year ended Dec. 31, 2008. Fourth Quarter and Year-Ended 2008 Financial Results Revenue for the fourth quarter of 2008 was $4.3 million compared with $5.7 million for the fourth quarter of 2007. Revenue for the year ended Dec. 31, 2008, was $16.5 million compared with $20.1 million for the year ended Dec. 31, 2007. Revenue in 2008 was earned...

2009-03-05 15:00:00

SEATTLE, March 5 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals Inc. (Nasdaq: TRBN) today announced that it plans to issue earnings results for the fourth quarter and year ended Dec. 31, 2008, after the close of market on March 12, 2009. The company's earnings conference call will take place March 12, 2009, at 2 p.m. Pacific Time, 5 p.m. Eastern Time. Both live events will be available for viewing on Trubion's website at http://investors.trubion.com. Fourth-Quarter and Year-Ended 2008...

2009-02-25 15:00:00

SEATTLE, Feb. 25 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals Inc. (Nasdaq: TRBN) today announced a work-force reduction of approximately 25 percent, or 25 employees, and a corporate restructuring. In the face of continuing uncertainty in the capital markets and the global economy, Trubion is proactively taking steps to reduce its costs and align its current resources with its strongest near-term opportunities while positioning the company for long-term sustainability and success....


Word of the Day
drawcansir
  • A blustering, bullying fellow; a pot-valiant braggart; a bully.
This word is named for Draw-Can-Sir, a character in George Villiers' 17th century play The Rehearsal.
Related